Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic ...

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using ...

(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced on Thursday that it has entered into a definitive agreement to acquire Dren Bio, Inc.'s DR-0201, a targeted ...

(RTTNews) - French pharmaceutical company Sanofi S.A. (SNYNF,SNY) said Tuesday that it completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager. Sanofi acquired DR-0201 from a ...

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...